Category Archives: cancer
2014-4742samples-21tumors-Cancer5000-set-254-genes
2015-MADGiC-identify-cancer-driver-gene
2014-REVIEW-identifying driver mutation in sequenced cancer genome
2014-review-Next-generation sequencing to guide cancer therapy
This reductionist thinking led the initial theories on carcinogenesis to be centered on how many “hits” or genetic mutations were necessary for a tumor to develop.
文献笔记-2015-nature-molecular analysis of gastric cancer新的分类及预后调查
文献:Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
A small pre-defined set of gene expression signatures
epithelial-to-mesenchymal transition (EMT) | 上皮细胞向间充质细胞转化 |
microsatellite instability (MSI) | 微卫星不稳定性 |
cytokine signaling | 细胞因子信号 |
cell proliferation | 细胞增殖 |
DNA methylation | DNA甲基化 |
TP53 activity | TP53活性 |
gastric tissue | 胃组织 |
经典的分类方法是:Gastric cancer may be subdivided into 3 distinct subtypes—proximal, diffuse, and distal gastric cancer—based on histopathologic and anatomic criteria. Each subtype is associated with unique epidemiology.
我们用主成分分析Principal component anaylsis (PCA)
PC1
PC2
PC3
这三个主成分与上面的七个特征是相关联的。
根据我们的主成分分析,可以把我们的300个GC样本分成如下四组,命名如下:
Gene expression signatures define four molecular subtypes of GC:
MSI (n = 68),
MSS/EMT (n = 46),
MSS/TP53+ (n = 79)
MSS/TP53− (n = 107)
然后用本文的分类方法,测试了另外另个published数据,还是分成四个组
(MSI, MSS/EMT, MSS/TP53+ and MSS/TP53-)
分别是TCGA数据库的;n = 46, n = 62, n = 50 and n = 47.
Singapore的研究; n = 12, n = 85, n = 39 and n = 63 respectively
我们这样的分组可以得到一些规律:
(i) The MSS/EMT subtype occurred at a significantly younger age (P = 3e-2) than did other subtypes. The majority (>80%) of the subjects in this subtype were diagnosed with diffuse-type (P < 1e-4) at stage III/IV(P = 1e-3).
(ii) The MSI subtype occurred predominantly in the antrum (75%), >60% of subjects had the intestinal subtype, and >50% of subjects were diagnosed at an early stage (I/II).
(iii) Epstein-Barr virus (EBV) infection occurred more frequently in the MSS/TP53+ group (n = 12/18, P = 2e-4) than in the other groups.
然后我们对我们的300个样本做了生存分析:
预后: MSI > MSS/TP53+ > MSS/TP53 > MSS/EMT
Next, we validated the survival trend of GC subtypes in three independent cohorts: Samsung Medical Center cohort 2 (SMC-2,n = 277, GSE26253)31,
Singapore cohort(n = 200, GSE15459)21 and
TCGA gastric cohort (n = 205).
We saw that the GC subtypes showed a significant association with overall survival
结论:我们这样的分类是最合理的,跟各个类别的预后非常相关。
然后我们看看突变模式:
the MSI~ hypermutation ~KRAS (23.3%), the PI3K-PTEN-mTOR pathway (42%), ALK (16.3%) and ARID1A (44.2%)18.
We observed enrichment of PIK3CA H1047R mutations in the MSI samples
we saw enrichment of E542K and E545K mutations in MSS tumors
The EMT subtype had a lower number of mutation events when compared to the other MSS groups(P = 1e−3).
The MSS/TP53− subtype showed the highest prevalence of TP53 mutations (60%), with a low frequency of other mutations
the MSS/TP53+ subtype showed a relatively higher prevalence (compared to MSS/TP53−) of mutations in APC, ARID1A, KRAS, PIK3CA and SMAD4.
再看看拷贝数变异情况:
再看看与另外两个研究团队的分类情况的比较
The TCGA study reported expression clusters (subtypes named C1–C4) and genomic subtypes (subtypes named EBV+, MSI, Genome Stable (GS) and Chromosomal Instability (CIN)).
A follow-up study of the Singapore cohort21 described three expression subtypes (Proliferative, Metabolic and Reactive)
However, a consensus on clinically relevant subtypes that encompasses molecular heterogeneity and that can be used in preclinical and clinical research has not been reported.
Here we report the molecular classification of GC linked not only to distinct patterns of genomic alterations, but also to recurrence pattern and prognosis across multiple GC cohorts.
microsatellite instability
英文简称 : MI
中文全称 : 微卫星不稳定性
所属分类 : 生物科学
词条简介 : 微卫星不稳定性(microsatellite instability,MI)检测是基于VNTR的发现,细胞内基因组含有大量的碱基重复序列,一般将6-7bp的串联重称为小卫星DNA(minisatellite DNA),又称为VNTR。而将1-4bp的串联重复称为微卫星DNA,又称简单重复序列(simple repeat sequence,SRS)。SRS是一种最常见的重复序列之一,具有丰富的多态性、高度杂合性、重组纺低等优点。最常见的为双核苷酸重复,即(AC)n和(TG)n。研究表胆,在n≥104时,2bp重复序列在人群中呈高度多态性。SRS广泛存在于原核和真核基因组中,约占真核基因组的5%,是近年来快速发展起来的新的DNA多态性标志之一。策卫星稳定性(MI)是指简重复序列的增加或丢失。MI首先在结肠癌中观察到,1993年在HNPCC中观察到多条染色体均有(AC)n重复序列的增加或毛失,以后相继在胃癌、胰腺癌、肺癌、膀胱癌、乳腺癌、前列腺癌及其他肿瘤等也好现存在微卫星不稳定现象,提示MI可能是肿瘤细胞的另一重要分子结果显示 ,MI与肿瘤与发展有关,MI仅在肿瘤细胞中发现,从未在正常组织中检测到。在原发与移肿瘤中,MI均交分布于整个肿瘤。晚期胃癌的MI频率显著高于早期胃癌。
文献笔记-2010-R-softeware-identify-cancer_driver_genes
我们用188 non-small cell lung tumors数据来测试了一个R语言程序,find driver genes in cancer ~
软件地址如下:http://linus.nci.nih.gov/Data/YounA/software.zip
这是一个R语言程序,里面有readme,用法很简单。
准备好两个文件,分别是silent_mutation_table.txt and nonsilent_mutation_table.txt ,它们都是普通文本格式数据,内容如下,就是把找到的snp格式化,根据注释结果分成silent和nonsilent即可。
#Ensembl_gene_id Chromosome Start_position Variant_Type Reference_Allele Tumor_Seq_Allele1 Tumor_Seq_Allele2 Tumor_Sample_Barcode
#ENSG00000122477 1 100390656 SNP G G A TCGA-23-1022-01A-02W-0488-09
然后直接运行程序包里面的主程序,在R语言里面source("main_R_script.r")
We reanalyzed sequence data for 623 candidate genes in 188 non-small cell lung tumors using the new method.
to identify genes that are frequently mutated and thereby are expected to have primary roles in thedevelopment of tumor
To find these driver genes, each gene is tested for whether its mutation rate is significantly higher than the background (or passenger) mutation rate.
Some investigators (Sjoblom et al., 2006) further divide mutations into several types according to the nucleotide and the neighboring nucleotides of the mutations.
Ding et al. (2008)的方法的三个缺点:
1、different types of mutations can have different impact on proteins.(越影响蛋白功能的突变,越有可能是driver mutation)
2、different samples have different background mutation rates. (在高突变背景的样本中的突变,很可能是高突变背景的原因,而不是因为癌症)
3、a different number of non-silent mutations can occur at each base pair according to the genetic code.(比如Tryptophan仅仅只有一个密码子,而arginine高达6个密码子)
我们提出的方法的4个优点是:
1,我们对非同义突变根据它们对蛋白功能的影响进行了评级打分。
2,我们允许不同的样品有着不同的BMR
3,that whether the mutation is non-silent or silent depends on the genetic code
4,we take into account uncertainties in the background mutation rate by using empirical Bayes methods
还有5个需要改进的地方:
1,However, the functional impact is also dependent on the position in which a mutation occurs.(我们仅仅考虑了突变对氨基酸的改变)
2,the current scoring system which assigns mutation scores in the order: missense mutation<inframe indel<mutation in splice sites<frameshift indel=nonsense mutation may be biased toward identifying tumor suppressor genes over oncogenes.
3,we may refine our background mutation model in Table 1 so that all six types of mutations, A:T→G:C, A:T→C:G, A: T→T :A,G:C→A:T, G:C→T :A, G:C→C:G have separate mutation rates.
4,we did not take into account correlations among mutations in identifying driver genes.
5,one might combine both copy number variation and sequencing data to identify driver genes.
HGNC定义的gene Symbol转为ensemble数据库的ID,的R语言代码:
library(biomaRt)
ensembl=useMart("ensembl",dataset = "hsapiens_gene_ensembl")
all.gene.table = read.table("all_gene.symbol", header=F)
convert=getBM(attributes = c("chromosome_name","ensembl_gene_id","hgnc_symbol"),filters =c("hgnc_symbol"),values=all.gene.table[,1],mart=ensembl)
chromosome=c(1:22,"X","Y","M")
convert=convert[!is.na(match(convert[,1],chromosome)),2:3] #remove names whose matching chromosome is not 1-22, X, or Y.
convert=convert[rowSums(convert=="")==0,]
write.table(convert,"ensembl2symbol.list",quote = F,row.names =F,col.names =F)
write.table(convert,"all_gene_name.txt",quote = F,row.names =F,col.names =F)
一个gene Symbol可能对应着多个ensemble ID号,但是在每个染色体上面是一对一的关系。
有些gene Symbol可能找不到ensemble ID号,一般情况是因为这个gene Symbol并不是纯粹的HGNC定义的,或者是比较陈旧的ID。
比如下面的TIGAR ,就很可能被写作是C12orf5
Aliases for TIGAR Gene
TP53 Induced Glycolysis Regulatory Phosphatase 2 3
TP53-Induced Glycolysis And Apoptosis Regulator 2 3 4
C12orf5 3 4 6
Probable Fructose-2,6-Bisphosphatase TIGAR 3
Fructose-2,6-Bisphosphate 2-Phosphatase 3
Chromosome 12 Open Reading Frame 5 2
Fructose-2,6-Bisphosphatase TIGAR 3
Transactivated By NS3TP2 Protein 3
EC 3.1.3.46 4
FR2BP 3
External Ids for TIGAR Gene
HGNC: 1185 Entrez Gene: 57103 Ensembl: ENSG00000078237 OMIM: 610775 UniProtKB: Q9NQ88
Previous HGNC Symbols for TIGAR Gene
C12orf5
Export aliases for TIGAR gene to outside databases
研究癌症领域必看文献
最近需要了解一些癌症相关知识,看到了这个文献列表,觉得非常棒,所以推荐给大家。
抽时间慢慢看,一个月应该可以把这些文献看完的。
癌症种类大全 http://www.cancer.gov/types
癌症药物大全 http://www.cancer.gov/about-cancer/treatment/drugs
癌症所有的信息几乎都能在这个网站上面找到 http://www.cancer.gov/
包括癌症的科普、treatment、diagnosis,prognosis,classification,drugs、prediction等等
Cancer Precision Medicine: Improving Evidence in Practice - August 24, 2015
NCI-MATCH Trial Opens, AACR blog post, August 2015
NCI-MATCH launch highlights new trial design in precision-medicine era
McNeal C , JNCI, August 2015
The Cancer Genomics Resource List, 2014
Zutter MM et al. CAP Lab Improvement Program,Archives of Pathology, August 2015
Personalized medicine and economic evaluation in oncology: all theory and no practice?
Garattini L et al. Expert Rev Pharmacoecon Outcomes Res 2015 Aug 9. 1-6
Precision medicine trials bring targeted treatments to more patients, C. Helwick, ASCO Post, Jul 25
Next-generation sequencing to guide cancer therapy
Gagan J et al, Genome Medicine, July 29, 2015
Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials.
Meric-Bernstam F et al. J. Clin. Oncol. 2015 May 26.
Brave-ish new world-what's needed to make precision oncology a practical reality.
MacConaill LE et al. JAMA Oncol 2015 Jul 16.
Genomic profiling: Building a continuum from knowledge to care
Helen C et al. JAMA Oncology, July 2015
Are we there yet?
When it comes to curing cancer, targeted therapies and genomic sequencing are helping, but we still have far to go. Genome Magazine, June 29, 2015
Artificial intelligence, big data, and cancer
Kantarjian H et al, JAMA Oncology, June 2015
Multigene panel testing in oncology practice - how should we respond?
Kurian AW et al. JAMA Oncology, June 2015
Use of whole genome sequencing for diagnosis and discovery in the cancer genetics clinic.
Foley SB et al. EBioMedicine 2015 Jan 2(1) 74-81
The future of molecular medicine: biomarkers, BATTLEs, and big data
ES Kim, ASCO University, June 2015
NCI-MATCH trial will link targeted cancer drugs to gene abnormalities
Targeted agent and profiling utilization registry study, from the American Society for Clinical Oncology
ASCO study aims to learn from patient access to targeted cancer drugs used off-label, American Society for Clinical Oncology
Improving evidence developed from population-level experience with targeted agents [PDF 462.93 KB]
McLellan M et al Issue Brief. Conference on Clinical Cancer Research November 2014
Implementing personalized cancer care.
Schilsky RL et al. Nat Rev Clin Oncol 2014 Jul (7) 432-8
Accelerating the delivery of patient-centered, high-quality cancer care.
Abrahams E et al. Clin. Cancer Res. 2015 May 15. (10) 2263-7
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
Catenacci DV et al. Mol Oncol 2015 May (5) 967-996
Cancer Precision Medicine: Improving Evidence in Practice - May 29, 2015
Diagnosis and treatment of cancer using genomics
Vockley JG et al. BMJ, May 28, 2015
Targeted agent and profiling utilization registry study, from the American Society for Clinical Oncology
ASCO study aims to learn from patient access to targeted cancer drugs used off-label, American Society for Clinical Oncology
Improving evidence developed from population-level experience with targeted agents [PDF 462.93 KB]
McLellan M et al Issue Brief. Conference on Clinical Cancer Research November 2014
Implementing personalized cancer care.
Schilsky RL et al. Nat Rev Clin Oncol 2014 Jul (7) 432-8
Accelerating the delivery of patient-centered, high-quality cancer care.
Abrahams E et al. Clin. Cancer Res. 2015 May 15. (10) 2263-7
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
Catenacci DV et al. Mol Oncol 2015 May (5) 967-996
Precision Medicine: Cancer and Genomics - May 12, 2015
Promise, peril seen in personalized cancer therapy,by Marie McCullough, Philadelphia Inquirer, May 10
A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F et al. J. Natl. Cancer Inst. 2015 Jul (7)
Divide and conquer: The molecular diagnosis of cancer, by Louis M. Staudt, National Cancer Insitute, Apr 13
Health: Make precision medicine work for cancer care
To get targeted treatments to more cancer patients pair genomic data with clinical data, and make the information widely accessible, Mark A. Rubin. Nature News, Apr 15
Using somatic mutations to guide treatment decisions
Horlings H et al. JAMA Oncology, March 12, 2015
The landscape of precision cancer medicine clinical trials in the United States
Roper N et al. Cancer Treatment Reviews 2015
What is “precision medicine? Information from the National Cancer Institute
Impact of cancer genomics on precision medicine for the treatment of cancer, from the Cancer Genome Atlas, NCI
US precision-medicine proposal sparks questions, by Sara Reardon, Nature News, Jan 22
Obama's 'precision medicine' means gene mapping,NBC News, Jan 21
What is President Obama's 'precision medicine' plan, and how might it help you? By Lenny Bernstein, Jan 21
Recent reviews
Companion diagnostics: the key to personalized medicine.
Jørgensen JT. Expert Rev Mol Diagn. 2015 Feb;15(2):153-6
Promoting precision cancer medicine through a community-driven knowledgebase.
Geifman N, et al. J Pers Med. 2014 Dec 15;4(4):475-88.
Toward a prostate cancer precision medicine.
Rubin MA. Urol Oncol. 2014 Nov 20.
Prioritizing targets for precision cancer medicine.
Andre F, et al. Ann Oncol. 2014 Dec;25(12):2295-303
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.
Yap TA, Popat S. Pharmgenomics Pers Med. 2014 Sep 19;7:285-95.
Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.
Pinto N, et al. J Oncol. 2014;936285
Translating genomics for precision cancer medicine.
Roychowdhury S, Chinnaiyan AM. Annu Rev Genomics Hum Genet. 2014;15:395-415
The Cancer Genome Atlas: Accomplishments and Future - April 3, 2015
The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak K, et al. Contemp Oncol (Pozn). 2015; 19(1A): A68-A77.
The Cancer Genome Atlas' 4th Annual Scientific Symposium
May 11-12 ~ Bethesda, MD
The Cancer Genome Atlas (TCGA) Data Portal
Portal provides a platform for researchers to search, download, and analyze data sets generated by TCGA
Cancer Genomics Hub: A resource of the National Cancer Institute, from the USC Genome Browser
Molecular classification of gastric adenocarcinoma: translating new insights from The Cancer Genome Atlas Research Network.
Sunakawa Y et al. Curr Treat Options Oncol 2015 Apr (4) 331
TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis.
Gore J et al. Oncotarget 2015 Feb 25.
Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group.
Shinagare AB et al. Abdom Imaging 2015 Mar 10.
Proteomics of colorectal cancer in a genomic context: First large-scale mass spectrometry-based analysis from the Cancer Genome Atlas.
Jimenez CR et al. Clin. Chem. 2015 Feb 26.
End of cancer-genome project prompts rethink
Geneticists debate whether focus should shift from sequencing genomes to analysing function. Heidi Ledford, Nature News and Comments, January 2015
Cancer Genomics: Insights into Driver Mutations - March 10, 2015
Seek and destroy: Relating cancer drivers to therapies
E. Martinez-Ledesma et al. Cell, March 9, 2015
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities
C Rubio-Perez et al. Cancer Cell, March 9, 2015
MADGiC: a model-based approach for identifying driver genes in cancer. [PDF 373.56 KB]
Keegan D. Korthauer et al. Bioinformatics, January 2015
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine.
Benjamin J Raphael et al. Genome Medicine 2014
Novel recurrently mutated genes in African American colon cancers.
Guda K et al. Proc Natl Acad Sci U S A. 2015 Jan 12
Sparse expression bases in cancer reveal tumor drivers.
Logsdon BA, et al. Nucleic Acids Res. 2015 Jan 12
Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles.
Bertrand D, et al. Nucleic Acids Res. 2015 Jan 8
Identification of constrained cancer driver genes based on mutation timing.
Sakoparnig T, et al. PLoS Comput Biol. 2015 Jan 8;11(1):e1004027
CaMoDi: a new method for cancer module discovery.
Manolakos A, et al. BMC Genomics. 2014 Dec 12;15 Suppl 10:S8.
VHL, the story of a tumour suppressor gene.
Gossage L, et al. Nat Rev Cancer. 2014 Dec 23;15(1):55-64
Targeting the MET pathway for potential treatment of NSCLC.
Li A, et al. Expert Opin Ther Targets. 2014 Dec 23:1-12
Deciphering oncogenic drivers: from single genes to integrated pathways.
Chen J, et al. Brief Bioinform. 2014 Nov 5.
Driver and passenger mutations in cancer.
Pon JR, et al. Annu Rev Pathol. 2014 Oct 17
Hereditary Cancer Genetic Testing: Where are We? - December 18, 2014
NCI paper:Prevalence and correlates of receiving and sharing high-penetrance cancer genetic test results: Findings from the Health Information National Trends Survey
Taber J.M. et al Public Health Genomics, January 2015
Clinical decisions: Screening an asymptomatic person for genetic risk--polling results
Schulte J, et al. N Engl J Med 2014 Nov;371(20):e30
Testing for hereditary breast cancer: Panel or targeted testing? Experience from a clinical cancer genetics practice.
Doherty J, J Genet Couns. 2014 Dec 5
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines.
Stoffel EM, et al. J Clin Oncol. 2014 Dec 1
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: A randomized controlled trial.
Manchanda R, et al. J Natl Cancer Inst. 2014 Nov 30;107(1)
Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing.
Manchanda R et al. J Natl Cancer Inst. 2014 Nov 30;107(1). pii: dju380. doi: 10.1093/jnci/dju380. Print 2015 Jan.
Check out our Cancer Genetic Testing Update Page for additional information and links
Cancer Genomic Tests (October 30, 2014)
Cancer Genomic Tests: Accelerating Translation - October 30, 2014
CDC-NCI paper: An overview of recommendations and translational milestones for genomic tests in cancer
Christine Q. Chang et al. Genetics in Medicine, October 22, 2014
Check out the CDC evidence-based classification of cancer genomic tests
Check out the NCI Cancer Genomics and Epidemiology Navigator for latest information on cancer genomic tests
EGAPP: A model process for evaluating genomic applications in practice and prevention. Check out cancer genomic tests, methods, evidence reviews and recommendation statements.
NCI Fact Sheet: Genetic testing for hereditary cancer syndromes
Cancer Genomics: Impact of Recent Insights - October 30, 2014
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.
Katherine A. Hoadley et al. Cell, August 2014
Genome study overhauls cancer categories, shifts from tissues to molecular subtypes, by Kevin Mayer, Genetics Bioengineering News, Aug 8
It's time for us to think about cancer differently, by Paula Mejia, Newsweek, Aug 8
NIH- The Cancer Genome Atlas (TCGA) Initiative
NIH information: What is cancer genomics and the genetic basis of cancer?
Cancer Precision Medicine: Where Are We? - September 18, 2014
NIH announces the launch of 3 integrated precision medicine trials; ALCHEMIST is for patients with certain types of early-stage lung cancer, August 2014
National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. Jeffrey Abrams et al. ASCO Annual Meeting 2014
Personalized medicine: Special treatment.
Michael Eisenstein. Nature, September 11, 2014
Why the controversy? Start sequencing tumor genes at diagnosis. Tumor sequencing at the time of diagnosis can give significant insight for successful cancer treatment, by Shelly Gunn, Genetic Engineering & Biotechnology News, Sep 10
National Cancer Institute information: Precision medicine and targeted therapy
Genomics and precision oncology: What's a targeted therapy for cancer? An updated list of approved drugs from the National Cancer Institute (2014)
Therapy: This time it's personal
Gravitz L Nature 509, S52-S54 2014 May 29
Multi-marker solid tumor panels using next-generation sequencing to direct molecularly targeted therapies
Michael Marrone, et al. PLoS Currents Evidence on Genomic Tests 2014 May 27
Impact of cancer genomics on precision medicine for the treatment of cancer, from the National Cancer Institute
Cancer genomics and precision medicine in the 21st century [PDF 2.20 MB], power point presentation from the National Human Genome Research Institute